Molina Healthcare's Third Quarter 2026 Earnings Conference Call - MOLINA HEALTHCARE INC

Explicit Guidance:

• FY2026 Premium Revenue: Reaffirmed at approximately $42 billion.
• FY2026 Adjusted EPS: Reaffirmed at at least $5.25 per share.
• FY2026 Segment Margins & Ratios:
  • Consolidated Medical Cost Ratio (MCR): 92.6%.
  • Consolidated G&A Ratio: 6.4%.
  • Medicaid MCR: 92.9% (unchanged).
  • Medicare MCR: 92.2% (unchanged).
  • Marketplace MCR: 90%.
• FY2026 Rate & Trend Outlook: Rates increased to 4.5% (from 4%); Medical Cost Trend increased to 5.5% (from 5%) to account for elevated utilization and acuity shifts.
• FY2027 Premium Revenue: Preliminary outlook set at at least $45 billion (down from prior $46.5 billion due to delayed Georgia/Texas contracts).
• FY2027 EPS Building Blocks: Preliminary sum exceeds $9.50 per share, comprising $5.25 (FY2026) + $4.00 (embedded earnings) + $0.75 (Marketplace break-even assumption), excluding legacy margin recovery.
• FY2027 Rate & Trend Outlook: Projected rates approx. 6%; Medical Cost Trend range of 5.5%–6.0% (includes 50 bps conservatism).
• FY2027 Embedded Earnings: Expectation to harvest $4.00 per share, composed of $1.50 from Florida CMS (current loss, future break-even), $1.00 from MAPD exit (non-recurring), and $1.50 from operating leverage on new contracts.

Business-Segment Outlook:

• Medicaid:
  • Growth: Expected to contribute ~$5.75 EPS for FY2026; long-term target margin of 2.5% by 2029 (from 1.6% in FY2026).
  • Membership: Projected 6% decline in FY2027 due to work requirements/re-verifications, with losses ramping gradually through 2027-2028; legacy business pre-tax margin expected at 1.6% for FY2026.
  • New Contracts: Florida CMS ($6B revenue) off to a strong start; Georgia and Texas contracts delayed, potentially commencing late 2027 or 2028, delaying $1.3B in premium.
  • Margin Trajectory: Legacy MCR expected to be flat or improve YoY if rates capture trend; current 1.6% margin viewed as the "trough."
• Medicare:
  • Duals: Core strategy driver; expected to contribute $1.25 EPS for FY2026 with 1.4% pre-tax margin; projected to grow profitably in FY2027.
  • MAPD: Expected to lose $1.00 EPS for FY2026; full exit scheduled for 2027.
  • Margins: Full-year MCR at 92.2%; Duals MCR ~92%; FY2027 margins anticipated to improve as MAPD losses cease.
• Marketplace:
  • Strategy: Reducing footprint to seven states while maintaining scale; expected loss of $0.75 EPS in FY2026 is not expected to recur in FY2027.
  • FY2027 Assumption: Building blocks assume Marketplace reaches at least break-even.
• RFP Pipeline:
  • Current Status: Bid for Texas Star Kids on hold; bids submitted for Missouri, Arizona; Indiana bid finalization imminent.
  • Value: Near-term RFPs represent ~$26B of a $90B total opportunity; high confidence in favorable award outcomes.

Market and Competitive Outlook:

• Demand & Membership: Anticipated 6% membership attrition in FY2027 due to federal work requirements and biannual re-verifications; states adopting policies (ex parte reviews, self-attestations) to limit disenrollment.
• Pricing Dynamics: January 1 renewal cohort (55% of premium) known rates average ~7%; overall 2027 rate increases estimated at ~6% to capture trend and acuity shifts.
• Acuity Shift: 1% of medical cost trend attributed to acuity shift from disenrollment; states beginning to incorporate prospective adjustments for this in rating baselines.
• Supply/Operational: Florida CMS contract (high acuity, complex behavioral/medical needs) operational implementation described as "nearly flawless" with 99% MLR and 5% pre-tax loss in Q4 2026; expected to reach break-even in 2027.

Macro / Industry Outlook:

• Regulation (Work Requirements): Federal work requirements and re-verifications expected to impact industry in 2027; 80% of states leaning toward enrollment-friendly interpretations; impacts on disenrollment expected to be phased through 2027-2029.
• Economic Environment: Medical cost trend plateauing but remaining elevated (5.5-6.0%); imbalance between rates and trend stabilizing.
• State Budgets: State actuaries increasingly using completed claims data and prospective acuity adjustments to rate adequacy, driven by cost pressures in high-cost drugs, LTSS, and behavioral health.
• Eligibility Changes: California asset limit reductions (July 2027) and other state-specific changes fully contemplated in membership outlooks.

Strategic Initiatives:

• Expansion: Full year realization of $6B Florida CMS contract expected to drive break-even status; Georgia and Texas contract implementation delayed to late 2027/2028.
• Divestiture: Complete exit from Medicare Advantage (MAPD) business by 2027.
• Operational Leverage: Anticipated $1.50 EPS benefit from G&A/operating leverage on new revenue in 2027.
• Capacity/Additions: No specific new facility capex mentioned; focus is on contractual capacity (RFPs) and operational scaling.

Risks and Headwinds to Outlook:

• Contract Delays: Judicial proceedings in Georgia and Texas could further delay contract commencement, pushing premium recognition into 2028.
• Regulatory Uncertainty: Actual impact of work requirements and re-verifications on membership may vary by state; 6% attrition assumption is a "best guess" but could be more severe or benign.
• Cost Trend Volatility: 50 basis points of conservatism in FY2027 trend estimate due to potential for higher-than-anticipated acuity shifts or trend spikes.
• New Contract Risks: Florida CMS contract ramp-up risks (operational or financial) could delay break-even timeline beyond 2027.
• State Budget Pressures: Potential state budget constraints could impact the timing or magnitude of rate adjustments.
• Marketplace Volatility: Reduced footprint may limit revenue upside if risk scores do not remain commensurate with acuity.

Management Tone on the Future:

• Confidence Level: High confidence in the "trough" being in place for Medicaid margins; optimistic about the rate cycle turning positive (Jan 1 renewals averaging 7%).
• Caveats/Hedges: Explicitly cautious on 2027 margin recovery until February guidance; 50 bps of conservatism built into trend estimates.
• Outlook Shift: View that the "temporary imbalance between rates and trend is gradually being corrected"; expect 2027 to show "profitable growth" driven by embedded earnings and rate adjustments.
• Strategic Focus: Bullish on RFP pipeline; confident in ability to manage high-acuity populations (Florida) and transition away from MAPD.

Miscellaneous:

• Balance Sheet: Parent cash balance ~$600M; net debt-to-cap ratio 44.4% (end of quarter); strong capital foundation supports growth.
• Embedded Earnings Definition: Defined as impact from known strategic initiatives (RFP wins/acquisitions), excluding legacy margin recovery.
• Reserves: Claims payable at 44% of reserves; actuarial process confidence remains high despite prior period development fluctuations.